JUNSHI BIO (01877) surged over 6%, and as of press time, the stock was up 6.34% to HK$31.54, with a turnover of HK$182 million.

On the news front, according to JUNSHI BIO's official announcement, the 2025 European Society for Medical Oncology (ESMO) Congress will be held from October 17 to October 21, 2025, in Berlin, Germany. More than 20 studies from JUNSHI BIO's innovative products, including anti-PD-1 monoclonal antibody Toripalimab, anti-BTLA monoclonal antibody tifcemalimab, and selective PI3K-α inhibitor JS105, will be presented at this conference.

Recently, the conference's official website announced the selection results for this year's Late-Breaking Abstracts (LBA). Two studies of Toripalimab were successfully selected for LBA oral presentations at the conference, with one study even making it into the conference's highest honor session - the Proffered Paper session LBA oral presentation, demonstrating the cutting-edge progress of Toripalimab combination therapies. Previously, the conference had already announced the selection status of other studies excluding LBA.